Elpiscience Biopharma and Astellas Pharma have teamed up in a deal for the BiME® platform, advancing two drugs, ES019 and a second molecular project.

Henlius Biotech and Sermonix Pharmaceuticals have formed a strategic alliance for the exclusive development, production, and commercialization of the investigational drug lasofoxifene in China.

Harbour Biomed and its subsidiary Nona Biosciences have entered an exclusive deal with Pfizer for the global development and commercialization of their anti-mesothelin ADC, HBM9033.

The CDE recently accepted Innovent Biologics and GenFleet Therapeutics' joint NDA for GF-105, prioritizing its review for advanced NSCLC patients with the KRAS G12C mutation after first-line therapy.

Abbisko Therapeutics entered into an exclusive license deal with Merck, Germany, for its CSF-1R inhibitor, Pimicotinib (ABSK021).

On Jan 2, 2024, MediLink Therapeutics and Roche entered a global deal to develop YL211, an ADC targeting c-MET for solid tumors.

On Dec 20, 2023, Hansoh Pharma and GSK unveiled an exclusive deal for the ADC new drug HS-20093, a Hansoh innovation.

Innovent Biologics and Sanegene Bio (Suzhou) announced their partnership to co-develop SGB-3908, an siRNA drug targeting AGT for hypertension treatment.

Suzhou Ribo Life Science recently inked a deal with Qilu Pharmaceutical, granting them rights to develop, produce, and market PCSK9 inhibitor drug RBD7022 (SR043) in Greater China.